Researchers urge caution in interpreting joint replacement predictors, noting that surgery reflects access and decision-making as well as disease biology.
Teriparatide followed by zoledronic acid increased bone mineral density but did not reduce fracture risk compared with standard care in adults with osteogenesis imperfecta.